Evox’s mission is to build a pipeline-driven platform technology company spearheading the development of exosome therapeutics for the treatment of serious, life-threatening diseases where there are limited treatment options for patients and their families.
What Are Exosomes?
Exosomes are increasingly seen as foundational transporters in the human body’s communication machinery and Evox’s technology development is unwaveringly focused on exploiting this natural mechanism for creating a novel form of biotherapeutics. Exosomes can transport various types of biomacromolecules – for instance, protein and nucleic acid-based therapeutics – but also various types of small molecule drugs.
Crucially, exosomes have also been found to improve the uptake of molecules across natural barriers such as the blood-brain barrier. Evox combines the highly versatile delivery capabilities of exosomes with targeting technology and sophisticated biomolecular engineering approaches. This, together with large-scale production methodologies, puts us at the forefront of developing natural delivery capabilities of exosomes for the treatment of severe diseases.
With its roots firmly grounded in two world-renowned academic institutions – Oxford University and the Karolinska Institute – Evox is driven by a dedication to scientific excellence and to pushing the scientific frontier together with an ecosystem of academic partners and collaborators worldwide.